Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital.

Autor: Mo Y; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University Pharmacy, Brooklyn, NY, USA., Karakas-Torgut A; Brookdale University Hospital and Medical Center, Brooklyn, NY, USA., Pham AQ; Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University Pharmacy, Brooklyn, NY, USA.
Jazyk: angličtina
Zdroj: Journal of pharmacy practice [J Pharm Pract] 2020 Apr; Vol. 33 (2), pp. 136-141. Date of Electronic Publication: 2018 Jul 13.
DOI: 10.1177/0897190018788264
Abstrakt: Objective: The aim of this study is to assess patterns of potential drug-drug interactions (DDIs) with direct oral anticoagulants (DOACs) in an inpatient hospital setting.
Methods: A retrospective chart review was conducted at the Brookdale University Hospital and Medical Center (BUHMC) from January 2014 to November 2016. All adult patients admitted to the BUHMC who were treated with a DOAC for at least 3 days were screened. Among them, those who received selected interacting drugs at any time during the course of DOAC therapy were included in this study.
Results: This study included 165 patients with an average of 73 years (standard deviation [SD] = 12.3) and 233 cases. The most commonly used concomitant drug with a DOAC was aspirin (58%), followed by amiodarone (16%) and P2Y 12 inhibitors (11%). The combined use of dual antiplatelet therapy and a DOAC was identified in 18 (6%) cases. Approximately one-third of the cases encountered were classified as the "avoidance" category.
Conclusions: Despite computerized DDI alerts, potentially significant DDIs with DOACs still occur. While the present study provides insight into the current patterns of DDIs, further studies are needed to evaluate clinical outcomes of the potential DDIs with DOACs in practice.
Databáze: MEDLINE
Externí odkaz: